[go: up one dir, main page]

MX2019012865A - Anticuerpos anti-interferon gamma y usos de los mismos. - Google Patents

Anticuerpos anti-interferon gamma y usos de los mismos.

Info

Publication number
MX2019012865A
MX2019012865A MX2019012865A MX2019012865A MX2019012865A MX 2019012865 A MX2019012865 A MX 2019012865A MX 2019012865 A MX2019012865 A MX 2019012865A MX 2019012865 A MX2019012865 A MX 2019012865A MX 2019012865 A MX2019012865 A MX 2019012865A
Authority
MX
Mexico
Prior art keywords
interfered
gamma antibodies
antibody
ifn
antibodies
Prior art date
Application number
MX2019012865A
Other languages
English (en)
Inventor
- Lun Ku Cheng
- Po SHIH Han
- Hao Lin Chia
- Ya Ding Jing
- Yi HUANG Jing
- Ting KUO Yi
Original Assignee
Elixiron Immunotherapeutics Hong Kong Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixiron Immunotherapeutics Hong Kong Ltd filed Critical Elixiron Immunotherapeutics Hong Kong Ltd
Publication of MX2019012865A publication Critical patent/MX2019012865A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporciona un anticuerpo anti-IFN-?. También se proporciona una composición que comprende el anticuerpo y la aplicación farmacéutica del anticuerpo para tratar un síndrome mediado por IFN-?.
MX2019012865A 2017-05-05 2018-05-07 Anticuerpos anti-interferon gamma y usos de los mismos. MX2019012865A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762501952P 2017-05-05 2017-05-05
PCT/CN2018/085836 WO2018202200A1 (en) 2017-05-05 2018-05-07 Anti-interferon gamma antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2019012865A true MX2019012865A (es) 2019-11-28

Family

ID=64015901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012865A MX2019012865A (es) 2017-05-05 2018-05-07 Anticuerpos anti-interferon gamma y usos de los mismos.

Country Status (13)

Country Link
US (3) US10968274B2 (es)
EP (1) EP3621993A4 (es)
JP (1) JP7308747B2 (es)
KR (1) KR102706285B1 (es)
CN (1) CN109715661B (es)
AU (1) AU2018263196B2 (es)
BR (1) BR112019022702A2 (es)
CA (1) CA3057735A1 (es)
IL (1) IL270308B2 (es)
MX (1) MX2019012865A (es)
TW (1) TWI797124B (es)
WO (1) WO2018202200A1 (es)
ZA (1) ZA201905642B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI797124B (zh) * 2017-05-05 2023-04-01 香港商安立璽榮生醫(香港)有限公司 抗干擾素-γ之抗體及其應用
JP2023507369A (ja) * 2019-12-20 2023-02-22 メディミューン，エルエルシー グリピカン３を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
CN112794903B (zh) * 2021-04-14 2021-06-25 广州市雷德生物科技有限公司 一种特异性结合IFN-γ的抗体及其应用
JP7359457B2 (ja) * 2021-10-11 2023-10-11 タグシクス・バイオ株式会社 自己免疫性疾患治療薬
CN118974079A (zh) 2022-03-22 2024-11-15 清迈大学 经修饰的干扰素γ蛋白质和其用途
JP2024021165A (ja) * 2022-08-03 2024-02-16 タグシクス・バイオ株式会社 ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
JP2024021164A (ja) * 2022-08-03 2024-02-16 タグシクス・バイオ株式会社 ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するハンナ型間質性膀胱炎治療薬
CN116284381B (zh) * 2023-05-16 2023-09-05 北京百普赛斯生物科技股份有限公司 抗IFN-γ的抗体及其应用
WO2025021953A1 (en) * 2023-07-25 2025-01-30 Cymab Aps Antigen-binding molecules capable of binding interferon gamma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US7335743B2 (en) 2002-10-16 2008-02-26 Amgen Inc. Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
BRPI0607238B8 (pt) 2005-01-27 2021-05-25 Novimmune Sa anticorpos anti-interferon gama humano, usos dos mesmos na preparação de medicamentos e composições farmacêuticas
WO2010047830A2 (en) 2008-10-24 2010-04-29 The Scripps Research Institute Agents for hcv treatment
KR20140097336A (ko) * 2011-11-23 2014-08-06 암젠 인크 인터페론 감마에 대한 항체를 이용한 치료 방법
TWI797124B (zh) * 2017-05-05 2023-04-01 香港商安立璽榮生醫(香港)有限公司 抗干擾素-γ之抗體及其應用
KR20200138167A (ko) * 2018-03-29 2020-12-09 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 Hbv 감염 치료 방법

Also Published As

Publication number Publication date
EP3621993A1 (en) 2020-03-18
CN109715661B (zh) 2022-06-14
US20210054066A1 (en) 2021-02-25
IL270308A (es) 2019-12-31
CA3057735A1 (en) 2018-11-08
AU2018263196A1 (en) 2019-09-26
WO2018202200A1 (en) 2018-11-08
AU2018263196B2 (en) 2024-11-07
BR112019022702A2 (pt) 2020-05-19
CN109715661A (zh) 2019-05-03
TWI797124B (zh) 2023-04-01
US12528862B2 (en) 2026-01-20
US12398205B2 (en) 2025-08-26
EP3621993A4 (en) 2021-04-07
ZA201905642B (en) 2020-07-29
JP2020519562A (ja) 2020-07-02
IL270308B2 (en) 2025-09-01
TW201904994A (zh) 2019-02-01
JP7308747B2 (ja) 2023-07-14
US20210171624A1 (en) 2021-06-10
KR102706285B1 (ko) 2024-09-12
US10968274B2 (en) 2021-04-06
US20210171625A1 (en) 2021-06-10
KR20200004292A (ko) 2020-01-13
IL270308B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
MX2019012865A (es) Anticuerpos anti-interferon gamma y usos de los mismos.
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
MX2019003780A (es) Uso de la combinación de anticuerpo anti-pd-1 e inhibidor de vegfr en la preparación de medicamentos para el tratamiento de cánceres.
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
MX2018016364A (es) Anticuerpos anti-pd-l1.
CL2018001705A1 (es) Composición farmacéutica que comprende lenalidomida amorfa y un antioxidante.
AR108468A1 (es) POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
CL2022000087A1 (es) Anticuerpo anti-tau y uso del mismo
MX2017001512A (es) Compuestos activos hacia bromodominios.
BR112021012037A2 (pt) Molécula anti-pd-1/il-7 bifuncional
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
BR112021012040A2 (pt) Molécula anti-pd-1/sirpa bifuncional
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
DOP2017000236A (es) Neutralización del virus chikungunya mediada por anticuerpos
UY37342A (es) Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
CR20180080A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
CL2017002680A1 (es) Construcciones de calicheamicina y sus métodos de uso
CL2018001129A1 (es) Parche adhesivo con huecos
CL2022001138A1 (es) Anticuerpos tmem219 y usos terapéuticos de los mismos
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.